NEW FDA ZEPBOUND WARNING!
VOTE FOR DAVE: https://tophost.org/2026/david-knappThe FDA just issued a NEW eye warning for EVERY GLP-1 medication, including Ozempic, Wegovy, Mounjaro, and Zepbound. But how worried should patients ...
10 Nov 28min
Novo's Next Weight Loss Pill Isn't a GLP-1, And That's HUGE
What if the next big breakthrough in obesity medicine isn't a GLP-1 at all?Novo Nordisk is developing an experimental oral weight-loss medication called LX9851, an ACSL5 inhibitor that targets an enti...
4 Nov 23min
Retatrutide Phase 3 Results: What You Need to Know
Retatrutide’s New Phase 3 Data, CagriSema in Menopause, and the Growing GLP‑1 Access CrisisHost Dave Knapp recaps major obesity-drug updates, focusing on Eli Lilly’s triple agonist retatrutide and Nov...
27 Okt 31min
GLP-1 Recall Update: Why You Need to Check Your Vials
Specific lots of compounded tirzepatide have been recalled over sterility concerns, another pharmacy recently recalled compounded semaglutide after particulate matter was identified, patients have rep...
20 Okt 27min
Eli Lilly vs. The Grey Market: The Future of Peptide Medicine
Eli Lilly’s fight over retatrutide may be about much more than one obesity drug.I’ve been covering retatrutide since early 2023, and since late 2024 I’ve been closely following the legal fight over wh...
14 Okt 25min
Ozempic & Zepbound Are Changing America in Ways Nobody Expected
Zepbound isn’t just changing people’s weight. GLP-1 medications are beginning to change America itself.Restaurants are rethinking what they serve. Grocery baskets are changing. Food companies are payi...
7 Okt 24min
They TRIPLED Wegovy Dose, Does it Beat Zepbound?
This week on On The Pen, The Weekly Dose, we break down one of the biggest weeks in obesity medicine coming out of EASD 2026.Eli Lilly says Zepbound may still outperform Wegovy 7.2 mg, even after Novo...
1 Okt 30min
